Ticker LaunchUplisting · BRTXD
BioRestorative Therapies, Inc.
Formerly Stem Cell Assurance, Inc.
BioRestorative Therapies, Inc. (BRTXD), already reporting to the SEC, moved up to Nasdaq Capital Market on Nov 9, 2021 with an offering at $10.00 per share raising $23M. Roth Capital was lead-left underwriter. Certilman Balin Adler & Hyman advised the company and Ellenoff Grossman & Schole advised the underwriters.
BioRestorative Therapies, Inc. is a life sciences company developing regenerative medicine therapies from adult stem cells. Its lead candidate, BRTX-100, uses a patient's own cultured mesenchymal stem cells for disc and spine disease, and a second program targets metabolic disorders.
- Status
- Uplisting
- Ticker
- BRTXD
- Exchange
- Nasdaq Capital Market
- Listed
- Nov 9, 2021
- Price
- $10.00
- Raised
- $23M
- Market cap at IPO price
- $34.9M
- First filed
- Jun 3, 2015
- Underwriters
- Roth Capital
- Company counsel
- Certilman Balin Adler & Hyman
- Underwriters' counsel
- Ellenoff Grossman & Schole
- Sector
- Healthcare
- Country / state
- NY
More on this listing for subscribers
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Registration statement (S-1) first filed Jun 3, 2015
- Latest amendment Nov 4, 2021
- Final prospectus (424B4) Nov 9, 2021
- All filings on EDGAR CIK 1505497
Other Healthcare uplistings in 2021
- Nexgel, Inc.NXGL · Dec 27, 2021 · $14.2M
- NutriBand Inc.NTRB · Oct 5, 2021 · $6.6M
- PetVivo Holdings, Inc.PETV · Aug 13, 2021 · $11.2M